REDMOND, Wash.--(BUSINESS WIRE)--EndoGastric Solutions, Inc.® (EGS) today announced the addition of two members to the executive leadership team. Brett Reynolds is appointed Chief Financial Officer, and Sarah Lyon joins as Vice President of Healthcare Economics, Reimbursement, and Policy. The addition of these executive team members will support the scale of the Company’s next growth and geographic expansion phase.
“I am pleased to welcome Mr. Reynolds and Ms. Lyon to our executive team,” said Darin Hammers, President, and Chief Executive Officer. “Their expertise and experience will be invaluable as we continue to change the standard of care for GERD treatment. I am confident they will provide strong leadership assistance and be an excellent addition to the EGS team.”
Brett Reynolds joins EndoGastric Solutions from Resonetics, where he served as Chief Financial Officer, driving financial strategy and performance since 2019. He brings an extensive background in profitability and cash flow enhancement, financial planning and analysis, revenue growth, mergers and acquisitions, financial systems, fundraising, strategic planning, and board and investor relations. Prior to Resonetics, Mr. Reynolds served as CFO at Cogentix Medical and Synovis Life Technologies. He is a Certified Public Accountant (inactive) and holds a bachelor’s degree in accounting and an MBA in finance, both from the University of Minnesota. With over 25 years of financial leadership experience, Mr. Reynolds will lead the EGS team to further growth and expansion.
Sarah Lyon’s experience spans over 15 years of increasing leadership roles in the medical device industry. Most recently, she served as Vice President, Market Access and Strategic Marketing for Respicardia, a company with a novel sleep medicine neurostimulation therapy that was acquired by ZOLL Medical. Before joining ZOLL Respicardia, Ms. Lyon spent 10 years at Medtronic driving new therapy commercialization in various leadership roles. She brings expertise in new technology commercialization, reimbursement and health economics, payer advocacy and pathway development. She also brings strategy consulting and financial services experience with a focus on healthcare M&A and commercial strategy. Ms. Lyon holds a Bachelor of Arts degree in economics from St. Olaf College and Master of Business Administration from The Wharton School of Business. She will work closely with the Executive Leadership team to improve patient access to the Transoral Incisionless Fundoplication (TIF) procedure by expanding payer coverage.
About GERD
Gastroesophageal reflux disease (GERD) affects nearly 20 percent of the U.S. population and is the most diagnosed gastrointestinal-related (GI) condition. Symptoms include heartburn, asthma, chronic cough, hoarseness, and occasionally chest pain. Treatments for GERD range from palliative care and medical management with proton pump inhibitors to surgery for many patients who opt for a more permanent treatment for their condition.
About EndoGastric Solutions® and Transoral Incisionless Fundoplication (TIF® 2.0 procedure) for GERD
Based in Redmond, Washington, EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technologies for the treatment of GERD, including the EsophyX device used to perform the TIF 2.0 procedure.
The TIF 2.0 procedure is a safe and effective alternative to surgery for treating GERD and GERD symptoms. Based on data from more than 140 peer-reviewed publications, most patients who received the TIF 2.0 procedure were able to eliminate use of daily medications for up to five years following their procedure. Over 35,000 TIF 2.0 procedures have been performed worldwide, with an exemplary safety profile. For more information, please visit www.GERDHelp.com.
Join the conversation on Twitter: @GERDHelp, Facebook: GERDHelp, Instagram: GERDHelp, and LinkedIn: EndoGastric Solutions
